Announcements

RB Press release - 08/01/2008
Reckitt Benckiser Receives Hart-Scott-Rodino Antitrust Clearance for Acquisition of Adams Respiratory Therapeutics

Reckitt Benckiser Group plc (RB.L) (“Reckitt Benckiser”) and Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) (“Adams”) announced today that they have received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) relating to the previously announced tender offer to purchase all of the outstanding shares of common stock of Adams. Reckitt Benckiser initiated, through its wholly owned subsidiary Twickenham Inc., a cash tender offer on December 21, 2007, to purchase all outstanding shares of common stock of Adams for US$60.00 per share. The tender offer will expire at 12:00 midnight, New York City time, on January 23, 2008, unless extended in accordance with the Merger Agreement entered into between Reckitt Benckiser, Twickenham and Adams and the applicable rules and regulations of the U.S. Securities and Exchange Commission (SEC). The offer remains subject to other customary conditions, including the acquisition by Twickenham of a majority of Adams’ shares of common stock on a fully diluted basis.  

For Further Information

Reckitt Benckiser

Mark Wilson, Corporate Controller and Investor Relations Manager (Investor Queries)
Fiona Fong, Head of Corporate Communications (Press Queries)
Tel: +44 (0)1753 217800

PR Agency
Susan Gilchrist, Brunswick, UK
Tel: +44 (0)207 404 5959

Cindy Leggett Flynn, Brusnwick, USA
Tel: +1 212 333 3810

Adams Respiratory Therapeutics
Janet M. Barth, SVP Investor Relations & Corporate Communications
Tel: +1 908 879 2428

Faith Pomeroy-Ward, Sr Manager Investor Relations & Corporate Communications
Tel: +1 908 879 1418